Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20117 plus Aumolertinib in advanced EGFR-mutated NSCLC
NCT06417008Phase 3Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- May 2024
- Primary completion
- Jun 2026
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of HS-20117-2 in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Hansoh Pharmaceutical Group. Started May 2024; status: recruiting.
02
Drugs
HS-20117-2
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT06417008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06417008.